TMCnet - World's Largest Communications and Technology Community



Research and Markets: 2014 Report on the US Predictive Breast Cancer Gene Testing Industry
[January 28, 2014]

Research and Markets: 2014 Report on the US Predictive Breast Cancer Gene Testing Industry

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "2014 Report on the US Predictive Breast Cancer Gene Testing Industry" report to their offering.

The incidence of breast cancer is increasing due to the increased life span and increasing adoption of Western lifestyle risk factors. Predictive breast cancer gene tests can be used to identify women who are at increased risk of developing hereditary breast cancer. The Predictive Breast Cancer Gene Testing market has seen exponential growth in the US, dominated by Myriad Genetics.

Gene testing in Europe is mostly carried out by the state funded health sector, but increasingly private companies are offering breast cancer gene tests to physicians. Myriad Genetics' position in the market is dependent on it being the leading provider of the most common breast cancer mutation.


  • An overview of Breast Cancer, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized US Breast Cancer Gene Testing market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
  • Investigation of current and future market competition for Breast Cancer Gene Testing
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Competitive Assessment

5 Unmet Needs

6 Pipeline Products

7 Industry Overview

8 Current and Future Players

9 Market Drivers, Opportunities and Barriers

10 US Outlook and Forecasts

11 Appendix

Companies Mentioned:

  • 23AndMe
  • Ambry Genetics
  • BGI-Shenzhen
  • Complete Genomics
  • Illumina
  • Life Technologies
  • Myriad Genetics
  • Navigenics (now Life Technologies)
  • PreventionGenetics
  • Roche

For more information visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy